logo

EVENT CALENDAR 2018

Calendario Ferias 2018

EVENT CALENDAR 2018

Leave a Comment / By

One more year, Moehs will participate in the most important fairs of the Pharma sector, betting on a close relationship with its customers and always willing to study new business relationships. You can find us at the following events:

* DCAT Week – March 19-22, 2018 – New York City

* CPhI Japan – April 18-20, 2018 – Tokyo

* CPhI North America – April 24-26, 2018 – Philadelphia, PA, USA

* CPhI China – June 20-22, 2018 – Shanghai / Hall E1, stand: E1A32

* CPhI Middle East & Africa – September 3-5, 2018 – ADNEC, Abu Dhabi, UAE

* Maghreb Pharma Expo 2018 – September 18-20, 2018 – SAFEX, Algiers, Algeria / Stand: C17

* CPhI Worldwide – October 9-11, 2018 – IFEMA Madrid, Spain / Hall:5 stand: 5D30

Contact us to organize a meeting!

Leave a Comment

Your email address will not be published. Required fields are marked *

logo
Twitter Linkedin-in
  • Headquarters:
  • Pol. Ind. Cova Solera
  • c/Roma, 8-12 08191 Rubí.
  • Barcelona (Spain)
  • T +34 93 586 05 20
  • Fax +34 93 588 85 13
  • info@moehs.es

Partnering companies

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF A STIMULATOR ACTIVE PRINCIPLE OF SOLUBLE CYCLASE GUANYLATE by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of an active ingredient that stimulates soluble guanylate cyclase.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2024 and they have a financeable budget of €1,862,213.00.
This project is co-financed by the European Union and CDTI.

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF AN ACTIVE INHIBITOR PRINCIPLE OF JANUS KINASE FOR THE TREATMENT OF ATOPIC DERMATITIS.”, by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of a janus kinase inhibitor active ingredient for the treatment of atopic dermatitis.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2025 and they have a financeable budget of €1,940,409.
This project is co-financed by the European Union and CDTI.